Durvalumab + Cisplatin + Carboplatin + Etoposide
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Extensive-stage Small Cell Lung Cancer
Conditions
Extensive-stage Small Cell Lung Cancer
Trial Timeline
Nov 11, 2021 → Jan 2, 2025
NCT ID
NCT04774380About Durvalumab + Cisplatin + Carboplatin + Etoposide
Durvalumab + Cisplatin + Carboplatin + Etoposide is a phase 3 stage product being developed by AstraZeneca for Extensive-stage Small Cell Lung Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT04774380. Target conditions include Extensive-stage Small Cell Lung Cancer.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04774380 | Phase 3 | Completed |
| NCT04870112 | Phase 1 | Terminated |
Competing Products
20 competing products in Extensive-stage Small Cell Lung Cancer